Consultation on the protection and enforcement of IP rights in third countries
Position Paper
25 Nov 2020
Healthcare, Intellectual property

The American Chamber of Commerce to the European Union (AmCham EU) welcomes the European Commission’s ongoing efforts to advance strong and balanced intellectual property rights (IPR) globally. Together with the EU Counterfeit and Piracy Watch List, the biannual report on the protection and enforcement of IPR in third countries is an important tool in assessing the scale and scope of the challenges being faced, and in determining where to focus the EU’s efforts. US businesses invested in and committed to Europe often rely on the appropriate legal frameworks in third countries regarding IPR. These US companies invest and innovate in a range of critical sectors, including life sciences, digital, audiovisual and consumer goods. Such innovations bring benefits to citizens, patients and consumers, as well as the broader economy – not just in Europe or the US, but across the globe.

We call upon the European Commission to strengthen its focus on securing sustainable improvements to the IP environment in third counties. The Commission’s work with third countries should include a focus on strengthening rules and technical capabilities of authorities, clear and measurable objectives in improving prosecution of bad actors, reduction of exported infringements and ease of resolving civil disputes between competitors. The mechanisms to support this may include further dialogue and engagement of third country governments and other stakeholders, technical programmes (eg, IP Key), negotiating ambitious IP provisions in EU Free Trade Agreements (FTAs), and critically the Commission’s new trade enforcement strategy, which strengthens the implementation and enforcement of EU trade policy, including for IP. In addition, we also encourage reinforcing existing collaborations, including with the US. AmCham EU stands ready to work with the European Commission in achieving those goals and in sharing insight on other countries and the IPR challenges faced by our companies globally.

Related items

News
4 May 2026

Discussing healthcare policy priorities in Strasbourg

On Tuesday, 28 to Wednesday, 29 April, AmCham EU travelled to the European Parliament in Strasbourg, France for a series of meetings with policymakers to discuss ongoing EU healthcare policy initiatives. The delegation met with Members of the European Parliament, Accredited Parliamentary Assistants and Group Policy Advisers, to discuss priorities for the EU’s health agenda. This included exchanges on how to strengthen Europe’s life sciences competitiveness and support resilient supply chains. Members also stressed the need for urgent action to simplify overlapping rules and reduce complexity. They underlined that proportionate, risk-based regulation is essential to support innovation. This approach can also help ensure timely patient access to medicines, medical technologies and diagnostics.

Healthcare
Read more
Read more about Discussing healthcare policy priorities in Strasbourg
News
21 Apr 2026

Navigating intellectual property in the age of artificial intelligence

On Tuesday, 21 April, AmCham EU hosted Renate Nikolay, Deputy Director-General, Directorate-General for Communications Networks, Content and Technology, European Commission, for a discussion on the growing impact of artificial intelligence (AI) on intellectual property (IP). At a time when AI is reshaping how content is created, used and shared, the exchange explored the increasing pressure on existing IP frameworks. Moderated by Carmen Lembo (Qualcomm), Chair, Intellectual Property Committee, AmCham EU, the discussion covered questions around copyright, AI training and transparency, while also highlighting the importance of a policy framework that protects rights and supports innovation in Europe’s evolving digital economy.

Intellectual property
Read more
Read more about Navigating intellectual property in the age of artificial intelligence
Position Paper
11 Nov 2025

Advancing short-term improvements to the EU Medical Devices and In Vitro Diagnostic Regulations

The Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) have created unworkable complexity for the medical devices industry, with dire consequences for European patients. To address these challenges, Members of the European Parliament (MEPs) or political groups can help address the unintended consequences of the current framework by tabling a Parliamentary Question that urges the European Commission to introduce targeted relief measures in parallel to a comprehensive revision of the MDR and IVDR. This would support the European Commission to implement short-term relief measures, in addition to the MDR/IVDR revision, that bolster efficiency, mitigate administrative bottlenecks and increase predictability in the regulatory processes. This would have an immediate impact on patient access and boost Europe’s innovation.

Healthcare
Read more
Read more about Advancing short-term improvements to the EU Medical Devices and In Vitro Diagnostic Regulations